The promise of artificial intelligence accelerating medical breakthroughs has largely remained theoretical—until now. A new computational framework demonstrates AI's capacity to independently formulate and test biological hypotheses about cancer, potentially transforming how we approach oncological research and drug discovery. The SPARK system represents a fundamental shift from AI as a tool that responds to human queries to AI as an autonomous scientific collaborator capable of original biological reasoning. Using natural language as its primary interface, SPARK analyzed data from 18 diverse cancer patient cohorts and successfully generated novel biological insights without human direction. The system's ability to process complex pathological data and formulate testable hypotheses marks a significant advancement in computational biology, where previous AI applications primarily focused on pattern recognition rather than hypothesis generation. This autonomous discovery capability could dramatically accelerate cancer research timelines by identifying biological relationships that human researchers might overlook or take years to conceptualize. However, the validation of AI-generated hypotheses remains critical—autonomous idea generation is only valuable if those ideas prove biologically meaningful and experimentally verifiable. The multicancer approach suggests SPARK's insights may reveal pan-cancer mechanisms rather than tumor-specific pathways, potentially identifying universal therapeutic targets. While promising, this technology raises important questions about the role of human intuition and domain expertise in scientific discovery. The framework's reliance on existing datasets also means it can only generate hypotheses based on current biological knowledge, potentially missing entirely novel mechanisms. Nevertheless, SPARK represents a paradigm shift toward AI-driven hypothesis generation that could fundamentally reshape cancer research methodology and accelerate therapeutic development.